Cargando…
Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study
Nivolumab has shown durable response and safety in patients with hepatocellular carcinoma (HCC) in previous trials. However, real-world data of nivolumab in HCC patients, especially those with Child–Pugh class B, are limited. To investigate the effectiveness and safety of nivolumab in a real-world c...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409289/ https://www.ncbi.nlm.nih.gov/pubmed/32698355 http://dx.doi.org/10.3390/cancers12071968 |
_version_ | 1783568032039174144 |
---|---|
author | Choi, Won-Mook Lee, Danbi Shim, Ju Hyun Kim, Kang Mo Lim, Young-Suk Lee, Han Chu Yoo, Changhoon Park, Sook Ryun Ryu, Min-Hee Ryoo, Baek-Yeol Choi, Jonggi |
author_facet | Choi, Won-Mook Lee, Danbi Shim, Ju Hyun Kim, Kang Mo Lim, Young-Suk Lee, Han Chu Yoo, Changhoon Park, Sook Ryun Ryu, Min-Hee Ryoo, Baek-Yeol Choi, Jonggi |
author_sort | Choi, Won-Mook |
collection | PubMed |
description | Nivolumab has shown durable response and safety in patients with hepatocellular carcinoma (HCC) in previous trials. However, real-world data of nivolumab in HCC patients, especially those with Child–Pugh class B, are limited. To investigate the effectiveness and safety of nivolumab in a real-world cohort of patients with advanced HCC, we retrospectively evaluated 203 patients with HCC who were treated with nivolumab between July 2017 and February 2019. Of 203 patients, 132 patients were classified as Child–Pugh class A and 71 patients were Child–Pugh class B. Objective response rate was lower in patients with Child–Pugh class B than A (2.8% vs. 15.9%; p = 0.010). Child–Pugh class B was an independent negative predictor for objective response. Median overall survival was shorter in Child–Pugh B patients (11.3 vs. 42.9 weeks; adjusted hazard ratio [AHR], 2.10; p < 0.001). In Child–Pugh B patients, overall survival of patients with Child–Pugh score of 8 or 9 was worse than patients with Child–Pugh score of 7 (7.4 vs. 15.3 weeks; AHR, 1.93; p < 0.020). In conclusion, considering the unsatisfactory response in Child–Pugh B patients, nivolumab may not be used in unselected Child–Pugh B patients. Further studies are needed in this patient population. |
format | Online Article Text |
id | pubmed-7409289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74092892020-08-25 Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study Choi, Won-Mook Lee, Danbi Shim, Ju Hyun Kim, Kang Mo Lim, Young-Suk Lee, Han Chu Yoo, Changhoon Park, Sook Ryun Ryu, Min-Hee Ryoo, Baek-Yeol Choi, Jonggi Cancers (Basel) Article Nivolumab has shown durable response and safety in patients with hepatocellular carcinoma (HCC) in previous trials. However, real-world data of nivolumab in HCC patients, especially those with Child–Pugh class B, are limited. To investigate the effectiveness and safety of nivolumab in a real-world cohort of patients with advanced HCC, we retrospectively evaluated 203 patients with HCC who were treated with nivolumab between July 2017 and February 2019. Of 203 patients, 132 patients were classified as Child–Pugh class A and 71 patients were Child–Pugh class B. Objective response rate was lower in patients with Child–Pugh class B than A (2.8% vs. 15.9%; p = 0.010). Child–Pugh class B was an independent negative predictor for objective response. Median overall survival was shorter in Child–Pugh B patients (11.3 vs. 42.9 weeks; adjusted hazard ratio [AHR], 2.10; p < 0.001). In Child–Pugh B patients, overall survival of patients with Child–Pugh score of 8 or 9 was worse than patients with Child–Pugh score of 7 (7.4 vs. 15.3 weeks; AHR, 1.93; p < 0.020). In conclusion, considering the unsatisfactory response in Child–Pugh B patients, nivolumab may not be used in unselected Child–Pugh B patients. Further studies are needed in this patient population. MDPI 2020-07-20 /pmc/articles/PMC7409289/ /pubmed/32698355 http://dx.doi.org/10.3390/cancers12071968 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Choi, Won-Mook Lee, Danbi Shim, Ju Hyun Kim, Kang Mo Lim, Young-Suk Lee, Han Chu Yoo, Changhoon Park, Sook Ryun Ryu, Min-Hee Ryoo, Baek-Yeol Choi, Jonggi Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study |
title | Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study |
title_full | Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study |
title_fullStr | Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study |
title_full_unstemmed | Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study |
title_short | Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study |
title_sort | effectiveness and safety of nivolumab in child–pugh b patients with hepatocellular carcinoma: a real-world cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409289/ https://www.ncbi.nlm.nih.gov/pubmed/32698355 http://dx.doi.org/10.3390/cancers12071968 |
work_keys_str_mv | AT choiwonmook effectivenessandsafetyofnivolumabinchildpughbpatientswithhepatocellularcarcinomaarealworldcohortstudy AT leedanbi effectivenessandsafetyofnivolumabinchildpughbpatientswithhepatocellularcarcinomaarealworldcohortstudy AT shimjuhyun effectivenessandsafetyofnivolumabinchildpughbpatientswithhepatocellularcarcinomaarealworldcohortstudy AT kimkangmo effectivenessandsafetyofnivolumabinchildpughbpatientswithhepatocellularcarcinomaarealworldcohortstudy AT limyoungsuk effectivenessandsafetyofnivolumabinchildpughbpatientswithhepatocellularcarcinomaarealworldcohortstudy AT leehanchu effectivenessandsafetyofnivolumabinchildpughbpatientswithhepatocellularcarcinomaarealworldcohortstudy AT yoochanghoon effectivenessandsafetyofnivolumabinchildpughbpatientswithhepatocellularcarcinomaarealworldcohortstudy AT parksookryun effectivenessandsafetyofnivolumabinchildpughbpatientswithhepatocellularcarcinomaarealworldcohortstudy AT ryuminhee effectivenessandsafetyofnivolumabinchildpughbpatientswithhepatocellularcarcinomaarealworldcohortstudy AT ryoobaekyeol effectivenessandsafetyofnivolumabinchildpughbpatientswithhepatocellularcarcinomaarealworldcohortstudy AT choijonggi effectivenessandsafetyofnivolumabinchildpughbpatientswithhepatocellularcarcinomaarealworldcohortstudy |